Role of Colesevelam in Combination Lipid-Lowering Therapy

American Journal of Cardiovascular Drugs

Volumn 13, Issue 5, 2013, Pages 315-323

  Jones, Michael R ^a   Nwose, Oliseyenum M ^b  

^a Daiichi Sankyo Inc ^*

^b DAIICHI SANKYO INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; BILE ACID SEQUESTRANT; C REACTIVE PROTEIN; COLESEVELAM; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIABETES MELLITUS; DRUG ABSORPTION; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; MONOTHERAPY; MYOPATHY; PRIORITY JOURNAL; RHABDOMYOLYSIS; SMALL INTESTINE ABSORPTION; TRIACYLGLYCEROL BLOOD LEVEL;

ALLYLAMINE; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; HYPERLIPIDEMIAS;

EID: 84885144524     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.1007/s40256-013-0037-0     Document Type: Article

References (69)

1. National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-421.
2. Grundy SM, Cleeman JI, Merz CNB, Brewer HB Jr, Clark LT, Hunninghake DB, et al; for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227-39.
3. Goodman DS, Hulley SB, Clark LT, Davis CE, Fuster V, LaRosa JC, et al. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med. 1988;148(1):36-69.
4. Gherondache CN, Pincus G. Metabolic changes induced in elderly patients with a cholesterol lowering resin, cholestyramine. Metabolism. 1964;13:1462-8.
5. Hashim SA, Vanitallie TB. Cholestyramine resin therapy for hypercholesteremia: clinical and metabolic studies. JAMA. 1965;192:289-93.
6. Casdorph HR. Hypercholesteremia - treatment with cholestyramine, a bile acid sequestering resin. Calif Med. 1967;106(4):293-5.
7. Glueck CJ, Ford S, Scheel D, Steiner P. Colestipol and cholestyramine resin. Comparative effects in familial type II hyperlipoproteinemia. JAMA. 1972;222:676-81.
8. Ryan JR, Jain A. The effect of colestipol or cholestyramine on serum cholesterol and triglycerides in a long-term controlled study. J Clin Pharmacol New Drugs. 1972;12(7):268-73.
9. Parkinson TM, Gundersen K, Nelson NA. Effects of colestipol (U-26,597A), a new bile acid sequestrant, on serum lipids in experimental animals and man. Atherosclerosis. 1970;11(3):531-7.
10. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984;251(3):351-64.
11. Angelin B, Eriksson M, Einarsson K. Combined treatment with cholestyramine and nicotinic acid in heterozygous familial hypercholesterolaemia: effects on biliary lipid composition. Eur J Clin Invest. 1986;16(5):391-6.
12. Kane JP, Malloy MJ, Tun P, Phillips NR, Freedman DD, Williams ML, et al. Normalization of low-density-lipoprotein levels in heterozygous familial hypercholesterolemia with a combined drug regimen. N Engl J Med. 1981;304(5):251-8.
13. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251(3):365-74.
14. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, for the West of Scotland Coronary Prevention Study Group, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333(20):1301-7.
15. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383-9.
16. Pearson TA, Laurora I, Chu H, Kafonek S. The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160(4):459-67.
17. Yan AT, Yan RT, Tan M, Hackam DG, Leblanc KL, Kertland H, The Vascular Protection (VP) and Guidelines Oriented Approach to Lipid Lowering (GOALL) Registries Investigators, et al. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med. 2006;119(8):676-83.
18. Bozentowicz-Wikarek M, Kocełak P, Smertka M, Olszanecka- Glinianowicz M, Chudek J. Effectiveness of lipid-lowering therapy with statins for secondary prevention of atherosclerosis - guidelines vs. reality. Pharmacol Rep. 2012;64(2):377-85.
19. Robinson JG, Ballantyne CM, Hsueh W, Rosen J, Lin J, Shah A, et al. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study). J Clin Lipidol. 2011;5(6):474-82.
20. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U, for the EUROASPIRE Study Group, et al. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009;373(9667):929-40.
21. Kotseva K, Wood D, De Backer G, EUROASPIRE Study Group, et al. EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries. Eur J Cardiovasc Prev Rehabil. 2010;17(5):530-40.
22. Mammen AL, Amato AA. Statin myopathy: a review of recent progress. Curr Opin Rheumatol. 2010;22(6):644-50.
23. Egan A, Colman E. Weighing the benefits of high-dose simvastatin against the risk of myopathy. N Engl J Med. 2011;365(4):285-7.
24. Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs. 2008;8(6):373-418.
25. Cham S, Evans MA, Denenberg JO, Golomb BA. Statin-associated muscle-related adverse effects: a case series of 354 patients. Pharmacotherapy. 2010;30(6):541-53.
26. Silva M, Matthews ML, Jarvis C, Nolan NM, Belliveau P, Malloy M, et al. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin Ther. 2007;29(2):253-60.
27. Study of the Effectiveness of Additional Reductions in Cholesterol Homocysteine Collaborative Group. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial. Lancet. 2010;376(9753):1658-69.
28. Cholesterol Treatment Trialists' (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581-90.
29. Mansi I, Frei CR, Pugh MJ, Makris U, Mortensen EM. Statins and musculoskeletal conditions, arthropathies, and injuries [published online ahead of print June 3, 2013]. JAMA Intern Med. doi: 10.1001/jamainternmed.2013.6184.
30. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735-42.
31. Zaharan NL, Williams D, Bennett K. Statins and risk of treated incident diabetes in a primary care population. Br J Clin Pharmacol. 2013;75(4):1118-24.
32. Danaei G, García Rodríguez LA, Fernandez Cantero O, Hernán MA. Statins and risk of diabetes: an analysis of electronic medical records to evaluate possible bias due to differential survival. Diabetes Care. 2013;36(5):1236-40.
33. Waters DD, Ho JE, Boekholdt SM, DeMicco DA, Kastelein JJP, Messig M, et al. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. J Am Coll Cardiol. 2013;61(2):148-52.
34. Preiss D, Seshasai SRK, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305(24):2556-64.
35. Rautio N, Jokelainen J, Oksa H, Saaristo T, Peltonen M, Vanhala M, et al. Do statins interfere with lifestyle intervention in the prevention of diabetes in primary healthcare? One-year follow-up of the FIN-D2D project. BMJ Open. 2012;2(5):e001472.
36. Sharma M, Ansari MT, Abou-Setta AM, Soares-Weiser K, Ooi TC, Sears M, et al. Systematic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia. Ann Intern Med. 2009;151(9):622-30.
37. American Diabetes Association. Standards of medical care in diabetes - 2013. Diabetes Care. 2013;36(Suppl 1):S11-66.
38. Reiner Ž, Catapano AL, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769-818.
39. Reiner Ž. Combined therapy in the treatment of dyslipidemia. Fundam Clin Pharmacol. 2010;24(1):19-28.
40. Davidson MH, Toth P, Weiss S, McKenney J, Hunninghake D, Isaacsohn J, et al. Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. Clin Cardiol. 2001;24(6):467-74.
41. Hunninghake D, Insull W Jr, Toth P, Davidson D, Donovan JM, Burke SK. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis. 2001;158(2):407-16.
42. Knapp HH, Schrott H, Ma P, Knopp R, Chin B, Gaziano JM, et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med. 2001;110(5):352-60.
43. Florentin M, Liberopoulos EN, Rizos CV, Kei AA, Liamis G, Kostapanos MS, et al. Colesevelam plus rosuvastatin 5 mg/day versus rosuvastatin 10 mg/day alone on markers of insulin resistance in patients with hypercholesterolemia and impaired fasting glucose. Metab Syndr Relat Disord. 2013;11(3):152-6.
44. Bays HE, Davidson M, Jones MR, Abby SL. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. Am J Cardiol. 2006;97(8):1198-205.
45. Jialal I, Abby SL, Misir S, Nagendran S. Concomitant reduction in low-density lipoprotein cholesterol and glycated hemoglobin with colesevelam hydrochloride in patients with type 2 diabetes: a pooled analysis. Metab Syndr Relat Disord. 2009;7(3):255-8.
46. Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones MR. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care. 2008;31(8):1479-84.
47. Goldberg RB, Fonseca VA, Truitt KE, Jones MR. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med. 2008;168(14):1531-40.
48. Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch Intern Med. 2008;168(18):1975-83.
49. Chapman MJ. Fibrates: therapeutic review. Br J Diabetes Vasc Dis. 2006;6(1):11-20.
50. McKenney J, Jones M, Abby S. Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia. Curr Med Res Opin. 2005;21(9):1403-12.
51. Welchol [package insert]. Parsippany, NJ: Daiichi-Sankyo, Inc.; 2013.
52. Davidson MH, Rooney M, Pollock EM, Drucker JL, Choy Y. The effect of colesevelam and niacin on low-density lipoprotein cholesterol and plasma glucose (abstr.). Circulation. 2012;126(21 Suppl):A11700.
53. The AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255-67.
54. HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events). http://www.thrivestudy.org. Accessed 21 June 2013.
55. Pandor A, Ara RM, Tumur I, Wilkinson AJ, Paisley S, Duenas A, et al. Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. J Intern Med. 2009;265(5):568-80.
56. Knopp RH, Tsunehara C, Retzlaff BM, Fish B, Nguyen H, Anderson S, et al. Lipoprotein effects of combined ezetimibe and colesevelam hydrochloride versus ezetimibe alone in hypercholesterolemic subjects: a pilot study. Metabolism. 2006;55(12):1697-703.
57. Bays H, Rhyne J, Abby S, Lai Y-L, Jones M. Lipid-lowering effects of colesevelam HCl in combination with ezetimibe. Curr Med Res Opin. 2006;22(11):2191-200.
58. Moore A, Phan BAP, Challender C, Williamson J, Marcovina S, Zhao X-Q. Effects of adding extended-release niacin and colesevelam to statin therapy on lipid levels in subjects with atherosclerotic disease. J Clin Lipidol. 2007;1(6):620-5.
59. Huijgen R, Abbink EJ, Bruckert E, Stalenhoef AFH, Imholz BPM, Durrington PN, for the Triple Study Group, et al. Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial. Clin Ther. 2010;32(4):615-25.
60. Brown KS, Armstrong IC, Wang A, Walker JR, Noveck RJ, Swearingen D, et al. Effect of the bile acid sequestrant colesevelam on the pharmacokinetics of pioglitazone, repaglinide, estrogen estradiol, norethindrone, levothyroxine, and glyburide. J Clin Pharmacol. 2010;50(5):554-65.
61. Donovan JM, Stypinski D, Stiles MR, Olson TA, Burke SK. Drug interactions with colesevelam hydrochloride, a novel, potent lipid-lowering agent. Cardiovasc Drugs Ther. 2000;14(6):681-90.
62. Wickremasingha P, He L, Lee J, Tao B, Mendell-Harary J, Walker J, et al. Lack of effect of colesevelam HCl on the single-dose pharmacokinetics of aspirin, atenolol, enalapril, phenytoin, rosiglitazone, and sitagliptin. Parsippany, NJ: Daiichi Sankyo, Inc., 2013. (Data on file).
63. He L, Wickremasingha P, Lee J, Tao B, Mendell-Harary J, Walker J, et al. The effects of colesevelam HCl on the single-dose pharmacokinetics of glimepiride, extended-release glipizide, and olmesartan medoxomil. Parsippany, NJ: Daiichi Sankyo, Inc., 2013. (Data on file).
64. Nakai A, Nishikata M, Matsuyama K, Ichikawa M. Drug interaction between simvastatin and cholestyramine in vitro and in vivo. Biol Pharm Bull. 1996;19(9):1231-3.
65. Kosoglou T, Statkevich P, Reyderman L, Pember LJC, Maxwell SE, Courtney R, et al. Effects of selected drugs on exposure to ezetimibe (abstr.). Eur Heart J. 2003;24(suppl):462.
66. Smith HT, Jokubaitis LA, Troendle AJ, Hwang DS, Robinson WT. Pharmacokinetics of fluvastatin and specific drug interactions. Am J Hypertens. 1993;6(11 Pt 2):375S-82S.
67. Forland SC, Feng Y, Cutler RE. Apparent reduced absorption of gemfibrozil when given with colestipol. J Clin Pharmacol. 1990;30(1):29-32.
68. Donovan JM, Kisicki JC, Stiles MR, Tracewell WG, Burke SK. Effect of colesevelam on lovastatin pharmacokinetics. Ann Pharmacother. 2002;36(3):392-7.
69. Jones MR, Baker BA, Mathew P. Effect of colesevelam HCl on single-dose fenofibrate pharmacokinetics. Clin Pharmacokinet. 2004;43(13):943-50.